Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AraC in Newly Diagnosed Acute Promyelocytic Leukemia (APL)
NCT00591526Phase 3Completed
- Sponsor
- GET-LAP
- Start
- Jun 2000
- Primary completion
- Jun 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of cytarabine in acute promyelocytic leukemia (APL) (4 arms), sponsored by GET-LAP. Primary endpoint: Relapse at 2 years. Started Jun 2000; status: completed.
02
Drugs
cytarabine
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT00591526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00591526.